Barclays
TMDX icon

Barclays’s Transmedics TMDX Stock Holding History

Barclays’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.9M Sell
190,578
-9,127
-5% -$1.19M ﹤0.01% 1126
2025
Q4 		$24.3M Sell
199,705
-2,153
-1% -$270K 0.01% 1143
2025
Q3 		$22.6M Buy
201,858
+16,434
+9% +$1.92M ﹤0.01% 1168
2025
Q2 		$24.8M Sell
185,424
-27,074
-13% -$2.97M 0.01% 1008
2025
Q1 		$14.3M Sell
212,498
-13,905
-6% -$956K ﹤0.01% 1196
2024
Q4 		$14.1M Buy
226,403
+35,603
+19% +$3.31M ﹤0.01% 1315
2024
Q3 		$30M Buy
190,800
+84,858
+80% +$13.1M 0.01% 873
2024
Q2 		$16M Sell
105,942
-91,649
-46% -$11M ﹤0.01% 1016
2024
Q1 		$14.6M Sell
197,591
-8,490
-4% -$700K 0.01% 1159
2023
Q4 		$16.3M Buy
206,081
+23,472
+13% +$1.42M 0.01% 1163
2023
Q3 		$10M Buy
182,609
+31,092
+21% +$2.24M 0.01% 993
2023
Q2 		$12.7M Buy
151,517
+135,977
+875% +$10.4M 0.01% 892
2023
Q1 		$1.18M Buy
15,540
+7,346
+90% +$508K ﹤0.01% 2606
2022
Q4 		$506K Buy
8,194
+6,900
+533% +$367K ﹤0.01% 3306
2022
Q3 		$54K Sell
1,294
-56
-4% -$2.44K ﹤0.01% 3758
2022
Q2 		$42K Sell
1,350
-2,972
-69% -$79.3K ﹤0.01% 4102
2022
Q1 		$116K Sell
4,322
-27,137
-86% -$486K ﹤0.01% 3715
2021
Q4 		$603K Buy
31,459
+20,866
+197% +$523K ﹤0.01% 3122
2021
Q3 		$350K Buy
10,593
+7,260
+218% +$222K ﹤0.01% 3357
2021
Q2 		$110K Sell
3,333
-17,686
-84% -$490K ﹤0.01% 3809
2021
Q1 		$872K Buy
21,019
+11,482
+120% +$353K ﹤0.01% 2861
2020
Q4 		$189K Sell
9,537
-1,963
-17% -$29K ﹤0.01% 3789
2020
Q3 		$158K Sell
11,500
-866
-7% -$14.8K ﹤0.01% 3998
2020
Q2 		$223K Buy
12,366
+7,634
+161% +$119K ﹤0.01% 3984
2020
Q1 		$57K Sell
4,732
-9,511
-67% -$159K ﹤0.01% 5148
2019
Q4 		$271K Buy
14,243
+10,980
+337% +$202K ﹤0.01% 4800
2019
Q3 		$77K Sell
3,263
-6,825
-68% -$164K ﹤0.01% 5669
2019
Q2 		$292K Buy
+10,088
New +$275K ﹤0.01% 4782

Other funds holding TMDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's TMDX Position: Q1 2026 in Review

Barclays reduced its Transmedics (TMDX) stake by 4.6% in Q1 2026, selling an estimated $1.19M and leaving 190,578 shares worth $18.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1126.

Barclays first reported a position in TMDX in Q2 2019 and has held it in 28 quarters since. The position peaked at $30M in Q3 2024. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

  • Barclays held 190,578 shares of Transmedics worth $18.9M as of Q1 2026.
  • Barclays sold 9,127 Transmedics shares in Q1 2026, an estimated $1.19M.
  • Transmedics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1126 holding.
  • Barclays first reported a position in Transmedics in Q2 2019 and has held it in 28 quarters since.
  • Barclays's Transmedics position peaked at $30M in Q3 2024.
  • 414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.